EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Evaluation of a novel 177Lu-labelled therapeutic Affibody molecule with a deimmunized ABD domain and improved biodistribution profile

Yongsheng Liu, Maryam Oroujeni, Yunqi Liao, Anzhelika Vorobyeva, Vitalina Bodenko, Anna Orlova, Mark Konijnenberg, Matilda Carlqvist, Elisabet Wahlberg, Annika Loftenius, Fredrik Y Frejd, Vladimir Tolmachev iD

European Journal of Nuclear Medicine and Molecular Imaging · 2024

DOI: 10.1007/s00259-024-06840-5 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, 2024. Verfasst von Yongsheng Liu und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, 751 85, Sweden. Hauptthemen laut MEDLINE: Lutetium, Radioisotopes, Erb-b2 Receptor Tyrosine Kinases. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Uppsala University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Fusion of Affibody molecules with an albumin-binding domain (ABD) provides targeting agents, which are suitable for radionuclide therapy. To facilitate clinical translation, the low immunogenic potential of such constructs with targeting properties conserved is required.

Methods

The HER2-targeting Affibody molecule ZHER2:2891 was fused with a deimmunized ABD variant and DOTA was conjugated to a unique C-terminal cysteine. The novel construct, PEP49989, was labelled with 177 Lu. Affinity, specificity, and in vivo targeting properties of [ 177 Lu]Lu-PEP49989 were characterised. Experimental therapy in mice with human HER2-expressing xenografts was evaluated.

Results

The maximum molar activity of 52 GBq/µmol [ 177 Lu]Lu-PEP49989 was obtained. [ 177 Lu]Lu-PEP49989 bound specifically to HER2-expressing cells in vitro and in vivo. The HER2 binding affinity of [ 177 Lu]Lu-PEP49989 was similar to the affinity of [ 177 Lu]Lu-ABY-027 containing the parental ABD035 variant. The renal uptake of [ 177 Lu]Lu-PEP49989 was 1.4-fold higher, but hepatic and splenic uptake was 1.7-2-fold lower than the uptake of [ 177 Lu]Lu-ABY-027. The median survival of xenograft-bearing mice treated with 21 MBq [ 177 Lu]Lu-PEP49989 (> 90 days) was significantly longer than the survival of mice treated with vehicle (38 days) or trastuzumab (45 days). Treatment using a combination of [ 177 Lu]Lu-PEP49989 and trastuzumab increased the number of complete tumour remissions. The renal and hepatic toxicity was minimal to mild.

Conclusion

In preclinical studies, [ 177 Lu]Lu-PEP49989 demonstrated favourable biodistribution and a strong antitumour effect, which was further enhanced by co-treatment with trastuzumab.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LutetiumRadioisotopesErb-b2 Receptor Tyrosine KinasesAnimalsMiceTissue DistributionHumansCell Line, TumorFemaleAlbuminsProtein DomainsIsotope LabelingRecombinant Fusion ProteinsRadiopharmaceuticals

Stichwörter der Autor:innen

Affibody moleculesAlbumin binding domainLutetium-177Therapy

Substanzen

LutetiumRadioisotopesErb-b2 Receptor Tyrosine KinasesAlbuminsRecombinant Fusion ProteinsRadiopharmaceuticalsLutetium-177

Autor:innen und Institutionen

  • Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, 751 85, Sweden.
  • Affibody AB, Solna, 171 65, Sweden.
  • Department of Medicinal Chemistry, Uppsala University, Uppsala, 751 23, Sweden.
  • Department of Radiology & Nuclear Medicine, Erasmus MC, Rotterdam, The Netherlands.
  • Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, 751 85, Sweden. vladimir.tolmachev@igp.uu.se.

ORCID-Profile: Vladimir Tolmachev

Förderung

  • Uppsala University

Zitieren

APA

Liu, Y., Oroujeni, M., Liao, Y., Vorobyeva, A., Bodenko, V., Orlova, A., Konijnenberg, M., Carlqvist, M., Wahlberg, E., Loftenius, A., Frejd, F. Y., & Tolmachev, V. (2024). Evaluation of a novel 177Lu-labelled therapeutic Affibody molecule with a deimmunized ABD domain and improved biodistribution profile. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-024-06840-5

Vancouver

Liu Y, Oroujeni M, Liao Y, Vorobyeva A, Bodenko V, Orlova A, et al. Evaluation of a novel 177Lu-labelled therapeutic Affibody molecule with a deimmunized ABD domain and improved biodistribution profile. European Journal of Nuclear Medicine and Molecular Imaging. 2024. doi:10.1007/s00259-024-06840-5

BibTeX
@article{Liu2024,
  author = {Liu, Yongsheng and Oroujeni, Maryam and Liao, Yunqi and Vorobyeva, Anzhelika and Bodenko, Vitalina and Orlova, Anna and Konijnenberg, Mark and Carlqvist, Matilda and Wahlberg, Elisabet and Loftenius, Annika and Frejd, Fredrik Y and Tolmachev, Vladimir},
  title = {Evaluation of a novel 177Lu-labelled therapeutic Affibody molecule with a deimmunized ABD domain and improved biodistribution profile},
  journal = {European Journal of Nuclear Medicine and Molecular Imaging},
  year = {2024},
  doi = {10.1007/s00259-024-06840-5}
}
Kostenlos starten →